top of page
Search

Navigating Access to Novel Targeted Therapies in China: A 2026 Clinical Guide


Key Takeaways

  • In May 2026, the NMPA approved three first-in-class innovative drugs addressing refractory HER2-positive gastric cancer (KN026), treatment-resistant hyperuricemia (SHR4640), and critical limb ischemia (NL003).  

  • Clinical data highlights a 19.6-month median overall survival for KN026 and a 66.67% ulcer healing rate for the NL003 plasmid gene therapy.  

  • International patients require precise medical record translation and multidisciplinary team (MDT) evaluations to determine baseline eligibility for these therapies.  

  • Cross-border healthcare coordination streamlines access, ensuring patients secure proper visa documentation and appointments at JCI-accredited or elite Tier-1 clinical facilities.  


The global medical landscape experienced a significant shift in May 2026 when the China National Medical Products Administration (NMPA) approved three milestone Class 1 innovative therapies. These breakthroughs include Enitocumab (KN026) for HER2-positive gastric cancer, Ruzinurad (SHR4640) for refractory gout, and Sedorming (NL003) for critical limb ischemia (CLI). For international patients who have exhausted standard treatment protocols in their home countries, accessing novel targeted therapies in China has emerged as a viable, data-backed pathway.  


A professional bilingual MedBridgeNZ medical concierge warmly welcoming an international patient at a Shanghai airport arrivals gate, holding a welcome sign and medical itinerary documents.
Navigating cross-border healthcare should be stress-free. A dedicated MedBridgeNZ bilingual concierge welcomes an international patient upon arrival in Shanghai, ensuring seamless, end-to-end logistics from the airport directly to Tier-1 clinical facilities.

Treatment Efficacy vs. Standard Care Outcomes

When evaluating international clinical pathways, analyzing the objective data of these newly approved therapies against existing global standards is essential.  

  • HER2-Positive Gastric Cancer (KN026 vs. Standard ADCs): In the KC-WISE clinical trial, the bispecific antibody KN026 combined with chemotherapy achieved a median overall survival (mOS) of 19.6 months (HR=0.29) and a median progression-free survival (mPFS) of 7.1 months. By contrast, the globally utilized standard ADC, Enhertu, demonstrated an mOS of 14.7 months in its DESTINY-Gastric04 trial.  

  • Refractory Gout (SHR4640 vs. Traditional Inhibitors): Traditional xanthine oxidase inhibitors like Allopurinol show limited target achievement rates (approximately 29.1% to 38.1%) for patients with renal excretion deficits. Ruzinurad (SHR4640), a highly selective URAT1 inhibitor, demonstrated a 52.6% single-time target achievement rate at week 16, notably avoiding the severe, irreversible hepatic and renal toxicities that caused earlier generation drugs (like Benzbromarone and Lesinurad) to be withdrawn from Western markets.  

  • Critical Limb Ischemia (NL003 vs. Amputation): For CLI patients without surgical revascularization options, amputation is often the default outcome. The NL003 plasmid gene therapy induces localized angiogenesis (biological bypass) via HGF expression, yielding a 56.25% complete pain resolution rate and a 66.67% total ulcer healing rate in clinical evaluations.


Top Hospital Options for International Patients

Selecting the right facility is critical when navigating the Chinese healthcare system. Recommended institutions typically feature dedicated international departments:


Ideal Candidates for Accessing Novel Targeted Therapies in China

Based on clinical indications, the following profiles are most suitable for evaluating this pathway:

  1. Refractory HER2-Positive Gastric Cancer Patients: Individuals who have previously failed standard first-line or second-line targeted therapies (such as Trastuzumab) and require advanced dual-epitope blockade interventions.  

  2. Patients with High-Risk, Treatment-Resistant Gout: High-net-worth individuals, particularly from regions with high-purine diets (such as the Middle East or Western nations), who suffer from severe hyperuricemia due to renal underexcretion and cannot tolerate standard XO inhibitors.  

  3. End-Stage CLI Patients Lacking Surgical Options: Diabetic or severe vascular disease patients classified under advanced Rutherford stages (e.g., Stage 5) who have been deemed ineligible for traditional bypass or endovascular stenting and face imminent amputation risks.


Who This Pathway is NOT Suitable For

This pathway is generally contraindicated for:

  • Patients whose conditions are well-controlled by standard, locally available first-line medications in their home country.

  • Individuals with severe cardiopulmonary instability or critical organ failure who are deemed medically unfit for international air travel.  

  • Patients seeking unproven or non-regulated alternative therapies, as access is strictly limited to NMPA-approved, evidence-based clinical protocols.  


Navigating international appointments and securing remote or face-to-face consultations with specialists in China can be complex; MedBridgeNZ assists international patients in bridging this gap by ensuring medical records are accurately translated and clinical channels are properly navigated.


Self-Arrangement vs. Coordinated Medical Access

Aspect

Self-Arrangement

Coordinated Access via MedBridgeNZ

Medical Translation

High risk of errors using non-clinical translators.

Clinical translation by specialized medical teams.  

Specialist Access

Prolonged wait times; difficult to identify true experts.

Direct routing to Tier-1 hospital MDT boards.  

Logistics

Complex visa procedures and unassisted travel.

Comprehensive medical visa support, VIP transfers, and on-ground bilingual support.  

Data Security

Vulnerable document transmission.

Secure, compliant transfer of sensitive pathology and imaging data.  

Clinical Case Studies: Patient Pathways and Outcomes

  • Patient Profile: A 68-year-old male from Southeast Asia with a history of severe Type 2 Diabetes and advanced Peripheral Arterial Disease (PAD).

  • Prior Treatment History: The patient had previously undergone two unsuccessful endovascular balloon angioplasties. Further surgical revascularization was ruled out due to diffuse distal arterial occlusion, and amputation of the lower left limb was recommended.

  • Clinical Rationale for China Pathway: The patient’s clinical profile aligned with the indications for the newly approved NL003 plasmid gene therapy to induce collateral angiogenesis.

  • Documented Outcomes: Following comprehensive medical review and localized intramuscular injections of NL003 at a designated Tier-1 facility in China, the patient demonstrated significant microvascular regeneration. At the 12-week follow-up, the patient exhibited complete resolution of resting pain and substantial healing of the ischemic ulcer, achieving a cost-effective limb-salvage outcome.

Please note: Individual medical outcomes vary significantly depending on baseline health, prior treatments, and specific disease progression.


Risks, Eligibility & Clinical Considerations

It is vital to understand that while these therapies represent significant advancements, they are not universal cures.  

  • Adverse Events: KN026 therapy may induce hematologic toxicities characteristic of concurrent chemotherapy regimens, though it demonstrates a low incidence of severe cardiac toxicity compared to older treatments. Gene therapies like NL003 require precise administration, and URAT1 inhibitors necessitate careful baseline renal assessment.  

  • Eligibility Thresholds: Strict baseline organ function, specific biomarker expressions (such as confirmed HER2-positivity via precise immunohistochemistry), and detailed prior treatment histories dictate patient eligibility.  

  • Clinical Boundaries: We strongly advise all patients to undergo a comprehensive evaluation with their Attending Doctor in their home country before making cross-border healthcare decisions. As a medical concierge provider, we exclusively facilitate preliminary medical record screenings and logistical coordination; we do not provide direct medical advice, diagnoses, or efficacy guarantees.


Frequently Asked Questions (FAQ)

What are the baseline requirements for accessing the NL003 gene therapy in China?

Patients must provide comprehensive medical records, including recent angiograms or Doppler ultrasounds confirming severe arterial occlusion where traditional surgical revascularization (bypass or stenting) is no longer a viable clinical option. Eligibility is ultimately determined by a specialized vascular surgeon in China following an MDT review.


Are the clinical outcomes of KN026 superior to current targeted therapies?

Based on the KC-WISE clinical study data, KN026 demonstrated a median overall survival of 19.6 months for patients with advanced HER2-positive gastric cancer, which presents a statistically significant extension compared to historical control data and certain existing standard therapies.  


How is the safety profile of SHR4640 different from older gout medications?

Unlike earlier generation uricosuric agents such as Benzbromarone or Lesinurad, which were associated with severe hepatic or renal toxicities, clinical trial data for SHR4640 indicates an excellent safety profile with no severe fatal adverse events leading to treatment discontinuation during the core study periods.  


Will I receive medical advice directly from the concierge service?

No. All medical decisions, including treatment eligibility and protocol design, are made exclusively by licensed, specialized physicians at the receiving clinical institutions in China. The concierge service manages language barriers, medical record formatting, and logistical coordination.  


Actionable Pathway for International Patients

Navigating complex healthcare systems across borders requires a structured, professionally managed approach. If you are considering accessing novel targeted therapies in China, follow this actionable pathway:  

  1. Initial Case Review: Provide us with your basic medical summaries, recent pathology reports, and imaging. Our team will format these for a preliminary review.

  2. Specialist Matching: We will securely route your formatted records to the appropriate multidisciplinary team (MDT) at a top-tier hospital in China to assess clinical feasibility.  

  3. On-the-Ground Coordination: Upon acceptance, we will assist with medical visa applications, book your face-to-face consultations, and manage all logistics, including bilingual clinical accompaniment.  


Simply submit your basic medical details on our Contact Us page, and our bilingual MedBridgeNZ Clinical Patient Care Team will respond within 24 hours to initiate your Free Assessment.


Disclaimer: MedBridgeNZ acts strictly as an international medical concierge and logistics coordinator. This content is for informational purposes only and should not be construed as professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding your medical condition.


References

Disclaimer: The content provided in this article is for informational and educational purposes only and does not substitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition.

bottom of page